Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Cash from Operations: 2023-2025

Historic Cash from Operations for Camp4 Therapeutics (CAMP) over the last 2 years, with Sep 2025 value amounting to -$11.2 million.

  • Camp4 Therapeutics' Cash from Operations fell 15.72% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.2 million, marking a year-over-year decrease of 2.42%. This contributed to the annual value of -$45.6 million for FY2024, which is 3.27% down from last year.
  • Latest data reveals that Camp4 Therapeutics reported Cash from Operations of -$11.2 million as of Q3 2025, which was down 8.60% from -$10.3 million recorded in Q2 2025.
  • Camp4 Therapeutics' 5-year Cash from Operations high stood at -$9.7 million for Q3 2024, and its period low was -$14.3 million during Q1 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$11.3 million (2024), whereas its average is -$11.7 million.
  • Within the past 5 years, the most significant YoY rise in Camp4 Therapeutics' Cash from Operations was 23.14% (2025), while the steepest drop was 28.33% (2025).
  • Quarterly analysis of 3 years shows Camp4 Therapeutics' Cash from Operations stood at -$11.8 million in 2023, then grew by 3.88% to -$11.3 million in 2024, then declined by 15.72% to -$11.2 million in 2025.
  • Its last three reported values are -$11.2 million in Q3 2025, -$10.3 million for Q2 2025, and -$14.3 million during Q1 2025.